Eric Venker Sells 315,522 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 315,522 shares of the firm’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $11.06, for a total value of $3,489,673.32. Following the sale, the chief operating officer now owns 959,457 shares in the company, valued at $10,611,594.42. This trade represents a 24.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Eric Venker also recently made the following trade(s):

• On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The stock was sold at an average price of $10.82, for a total value of $4,701,051.96.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.65, for a total value of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total transaction of $2,090,958.00.

Roivant Sciences Stock Up 0.4 %

ROIV traded up $0.04 during trading on Monday, reaching $10.83. The company’s stock had a trading volume of 6,976,198 shares, compared to its average volume of 5,636,264. The company has a market cap of $7.73 billion, a price-to-earnings ratio of -72.20 and a beta of 1.26. The firm has a fifty day simple moving average of $10.78 and a two-hundred day simple moving average of $11.46. Roivant Sciences Ltd. has a 1 year low of $9.93 and a 1 year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, equities analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ROIV shares. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Roivant Sciences has an average rating of “Buy” and an average price target of $18.08.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ROIV. Nordea Investment Management AB increased its position in Roivant Sciences by 22.5% during the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock worth $3,306,000 after purchasing an additional 52,031 shares during the last quarter. TOMS Capital Investment Management LP acquired a new stake in shares of Roivant Sciences during the 3rd quarter worth approximately $46,333,000. Barclays PLC raised its position in shares of Roivant Sciences by 19.7% during the 3rd quarter. Barclays PLC now owns 459,521 shares of the company’s stock valued at $5,302,000 after buying an additional 75,609 shares during the period. Loomis Sayles & Co. L P lifted its holdings in Roivant Sciences by 13.3% in the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock valued at $45,147,000 after acquiring an additional 458,601 shares during the last quarter. Finally, Retirement Systems of Alabama grew its position in Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock worth $6,116,000 after acquiring an additional 112,286 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.